Nanoparticle-mediated drug delivery for treating melanoma

Nanomedicine

Volumn 10, Issue 16, 2015, Pages 2613-2633

  Mundra, Vaibhav ^a   Li, Wei ^b   Mahato, Ram I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

active targeting; metastatic melanoma; multidrug resistance; nanoparticles; photodynamic therapy; polymer drug conjugate; tumor initiating cells

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; NANOPARTICLE; DACARBAZINE;

ANTINEOPLASTIC ACTIVITY; BASE PAIRING; CANCER RESISTANCE; CANCER STEM CELL; CIRCULATING TUMOR CELL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ENVIRONMENTAL FACTOR; HUMAN; HYDROGEN BOND; KERATINOCYTE; MELANOCYTE; MELANOMA; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PARACRINE SIGNALING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SITE DIRECTED MUTAGENESIS; TUMOR MICROENVIRONMENT; ULTRAVIOLET RADIATION; PATHOLOGY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; DACARBAZINE; DRUG DELIVERY SYSTEMS; HUMANS; MELANOMA; NANOPARTICLES; SKIN NEOPLASMS;

EID: 84940497441     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.111     Document Type: Review

References (209)

1. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 16(1), 5-24 (2011
2. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev. Anticancer Ther. 10(11), 1811-1823 (2010
3. Sun C, Wang L, Huang S., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 508(7494), 118-122 (2014
4. Nazarian R, Shi H, Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 468(7326), 973-977 (2010
5. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23(6), 488-496 (2009
6. Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature. 445(7130), 843-850 (2007
7. Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem. Photobiol. 84(3), 539-549 (2008
8. Halaban R, Langdon R, Birchall N., et al. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J. Cell Biol. 107(4), 1611-1619 (1988
9. Alanko T, Rosenberg M, Saksela O. FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. J. Invest. Dermatol. 113(1), 111-116 (1999
10. Marconi A, Terracina M, Fila C., et al. Expression and function of neurotrophins and their receptors in cultured human keratinocytes. J. Invest. Dermatol. 121(6), 1515-1521 (2003
11. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J. Investig. Dermatol. Symp. Proc. 10(2), 153-163 (2005
12. Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenviron. 1(1), 93-102 (2008
13. Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A. Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Ann. Oncol. 26(1), 33-39 (2015
14. Galanzha EI, Zharov VP. Circulating tumor cell detection and capture by photoacoustic flow cytometry in vivo and ex vivo. Cancers (Basel) 5(4), 1691-1738 (2013
15. Galanzha EI, Shashkov EV, Spring PM, Suen JY, Zharov VP. In vivo noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res. 69(20), 7926-7934 (2009
16. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc. Natl Acad. Sci. USA. 88(14), 6028-6032 (1991
17. Kim E, Rebecca V, Fedorenko IV., et al. Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach. Cancer Res. 73(23), 6874-6885 (2013
18. Balsamo M, Scordamaglia F, Pietra G., et al. Melanomaassociated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl Acad. Sci. USA. 106(49), 20847-20852 (2009
19. Waster P, Rosdahl I, Gilmore BF, Seifert O. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-Alpha in fibroblasts: implications for melanoma invasion. Int. J. Oncol. 39(1), 193-202 (2011
20. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanomastromal fibroblast interactions: when seeds meet soil. Oncogene. 22(20), 3162-3171 (2003
21. Pietras K, Rubin K, Sjoblom T., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62(19), 5476-5484 (2002
22. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat. Rev. Cancer. 4(10), 806-813 (2004
23. Curti BD, Urba WJ, Alvord WG., et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 53(10 Suppl.), 2204-2207 (1993
24. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer. 4(11), 839-849 (2004
25. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110(4), 475-482 (2002
26. Moschetta M, Pretto F, Berndt A., et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDAfibronectin-positive metastatic human melanoma xenografts. Cancer Res. 72(7), 1814-1824 (2012
27. Penson RT, Oliva E, Skates SJ., et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol. Oncol. 93(1), 98-106 (2004
28. Kim YH, Ishii G, Goto K., et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer. 65(1), 105-111 (2009
29. Mignogna C, Staibano S, Altieri V., et al. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer. 6, 293 (2006
30. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol. Cancer Ther. 4(5), 855-863 (2005
31. Wind NS, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int. J. Breast Cancer 2011, 967419 (2011
32. Ichihashi N, Kitajima Y. Chemotherapy induces or increases expression of multidrug resistance-Associated protein in malignant melanoma cells. Br. J. Dermatol. 144(4), 745-750 (2001
33. Colone M, Calcabrini A, Toccacieli L., et al. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J. Invest. Dermatol. 128(4), 957-971 (2008
34. Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 18(7), 1863-1869 (2012
35. Triller N, Korosec P, Kern I, Kosnik M, Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer. 54(2), 235-240 (2006
36. Calatozzolo C, Gelati M, Ciusani E., et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J. Neurooncol. 74(2), 113-121 (2005
37. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 24(54), 8061-8075 (2005
38. Berg SL, Tolcher A, O'Shaughnessy JA., et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol. 13(8), 2039-2042 (1995
39. Advani R, Fisher GA, Lum BL., et al. A Phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin. Cancer Res. 7(5), 1221-1229 (2001
40. Kelly RJ, Draper D, Chen CC., et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res. 17(3), 569-580 (2011
41. Luo Y, Ellis LZ, Dallaglio K., et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J. Invest. Dermatol. 132(10), 2440-2450 (2012
42. Wouters J, Stas M, Gremeaux L., et al. The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS ONE. 8(10), e76550 (2013
43. Chen KG, Szakacs G, Annereau JP., et al. Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res. 18(2), 102-112 (2005
44. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 414(6859), 105-111 (2001
45. Lee N, Barthel SR, Schatton T. Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab. Invest. 94(1), 13-30 (2014
46. Civenni G, Walter A, Kobert N., et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-Term growth. Cancer Res. 71(8), 3098-3109 (2011
47. Reid AL, Millward M, Pearce R., et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br. J. Dermatol. 168(1), 85-92 (2013
48. Schatton T, Murphy GF, Frank NY., et al. Identification of cells initiating human melanomas. Nature. 451(7176), 345-349 (2008
49. Chartrain M, Riond J, Stennevin A., et al. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS ONE. 7(5), e36762 (2012
50. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc. Natl Acad. Sci. USA. 108(6), 2474-2479 (2011
51. Pinc A, Somasundaram R, Wagner C., et al. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol. Ther. 20(5), 1056-1062 (2012
52. Monzo M, Rosell R, Sanchez JJ., et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-Tubulin gene mutations. J. Clin. Oncol. 17(6), 1786-1793 (1999
53. Kelley MJ, Li S, Harpole DH. Genetic analysis of the betatubulin gene, TUBB, in non-small-cell lung cancer. J. Natl Cancer Inst. 93(24), 1886-1888 (2001
54. Mesquita B, Veiga I, Pereira D., et al. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer. 5, 101 (2005
55. Sale S, Sung R, Shen P., et al. Conservation of the class I betatubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol. Cancer Ther. 1(3), 215-225 (2002
56. Wang Y, Yin S, Blade K, Cooper G, Menick DR, Cabral F. Mutations at leucine 215 of beta-Tubulin affect paclitaxel sensitivity by two distinct mechanisms. Biochemistry. 45(1), 185-194 (2006
57. Yin S, Cabral F, Veeraraghavan S. Amino acid substitutions at proline 220 of beta-Tubulin confer resistance to paclitaxel and colcemid. Mol. Cancer Ther. 6(10), 2798-2806 (2007
58. Hari M, Loganzo F, Annable T., et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-Tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5(2), 270-278 (2006
59. Giannakakou P, Sackett DL, Kang YK., et al. Paclitaxelresistant human ovarian cancer cells have mutant beta-Tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272(27), 17118-17125 (1997
60. Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in alpha- And beta-Tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol. Cancer Ther. 2(7), 597-605 (2003
61. Mozzetti S, Ferlini C, Concolino P., et al. Class III betatubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11(1), 298-305 (2005
62. Leskela S, Leandro-Garcia LJ, Mendiola M., et al. The miR-200 family controls beta-Tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr. Relat. Cancer. 18(1), 85-95 (2010
63. Ploussard G, Terry S, Maille P., et al. Class III beta-Tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 70(22), 9253-9264 (2010
64. Roque DM, Bellone S, English DP., et al. Tubulin-beta-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. 119(14), 2582-2592 (2013
65. Kamath K, Wilson L, Cabral F, Jordan MA. BetaIIItubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 280(13), 12902-12907 (2005
66. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III beta-Tubulin sensitize drugresistant cells to Taxol. Br. J. Cancer. 80(7), 1020-1025 (1999
67. Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. Class III beta-Tubulin expression and in vitro resistance to microtubule targeting agents. Br. J. Cancer. 102(2), 316-324 (2010
68. Levallet G, Bergot E, Antoine M., et al. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol. Cancer Ther. 11(5), 1203-1213 (2012
69. Narvi E, Jaakkola K, Winsel S., et al. Altered TUBB3 expression contributes to the epothilone response of mitotic cells. Br. J. Cancer. 108(1), 82-90 (2013
70. Gan PP, Pasquier E, Kavallaris M. Class III beta-Tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 67(19), 9356-9363 (2007
71. Akasaka K, Maesawa C, Shibazaki M., et al. Loss of class III beta-Tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J. Invest. Dermatol. 129(6), 1516-1526 (2009
72. Locher H, de Rooij KE, de Groot JC., et al. Class III betatubulin, a novel biomarker in the human melanocyte lineage. Differentiation. 85(4-5), 173-181 (2013
73. Dalziel M, Kolesnichenko M, das Neves RP, Iborra F, Goding C, Furger A. Alpha-MSH regulates intergenic splicing of MC1R and TUBB3 in human melanocytes. Nucleic Acids Res. 39(6), 2378-2392 (2011
74. Mhaidat NM, Thorne RF, de Bock CE, Zhang XD, Hersey P. Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-Tubulin levels. FEBS Lett. 582(2), 267-272 (2008
75. Patel KJ, Lee C, Tan Q, Tannock IF. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin. Cancer Res. 19(24), 6766-6776 (2013
76. Gotink KJ, Broxterman HJ, Labots M., et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17(23), 7337-7346 (2011
77. Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer. 8, 175-2407-8-175 (2008
78. Swietach P, Hulikova A, Patiar S, Vaughan-Jones RD, Harris AL. Importance of intracellular pH in determining the uptake and efficacy of the weakly basic chemotherapeutic drug, doxorubicin. PLoS ONE. 7(4), e35949 (2012
79. Federici C, Petrucci F, Caimi S., et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS ONE. 9(2), e88193 (2014
80. Fan S, Niu Y, Tan N., et al. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. Oncogene. 32(13), 1682-1690 (2013
81. Chapuy B, Koch R, Radunski U., et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia. 22(8), 1576-1586 (2008
82. Ouar Z, Lacave R, Bens M, Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells. Cell Biol. Toxicol. 15(2), 91-100 (1999
83. Chen KG, Valencia JC, Gillet JP, Hearing VJ, Gottesman MM. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell. Melanoma Res. 22(6), 740-749 (2009
84. Chen KG, Valencia JC, Lai B., et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc. Natl Acad. Sci. USA. 103(26), 9903-9907 (2006
85. Xie T, Nguyen T, Hupe M, Wei ML. Multidrug resistance decreases with mutations of melanosomal regulatory genes. Cancer Res. 69(3), 992-999 (2009
86. Chen KG, Leapman RD, Zhang G., et al. Influence of melanosome dynamics on melanoma drug sensitivity. J. Natl Cancer Inst. 101(18), 1259-1271 (2009
87. Ma XH, Piao S, Wang D., et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin. Cancer Res. 17(10), 3478-3489 (2011
88. Hertzman Johansson C, Azimi A, Frostvik Stolt M., et al. Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Res. 23(5), 360-365 (2013
89. O'Brien ME, Wigler N, Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15(3), 440-449 (2004
90. Rademaker-Lakhai JM, Crul M, Zuur L., et al. Relationship between cisplatin administration and the development of ototoxicity. J. Clin. Oncol. 24(6), 918-924 (2006
91. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 303(5665), 1818-1822 (2004
92. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today. 8(6), 259-266 (2003
93. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986
94. Noguchi Y, Wu J, Duncan R., et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89(3), 307-314 (1998
95. Yokoyama M, Miyauchi M, Yamada N., et al. Characterization and anticancer activity of the micelleforming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. 50(6), 1693-1700 (1990
96. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J. Control. Release. 70(1-2), 63-70 (2001
97. Liu J, Zeng F, Allen C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur. J. Pharm. Biopharm. 65(3), 309-319 (2007
98. Ramaswamy M, Zhang X, Burt HM, Wasan KM. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J. Pharm. Sci. 86(4), 460-464 (1997
99. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release. 70(1-2), 1-20 (2001
100. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control. Release. 109(1-3), 169-188 (2005
101. Gaucher G, Marchessault RH, Leroux JC. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J. Control. Release. 143(1), 2-12 (2010
102. Kim S, Shi Y, Kim JY, Park K, Cheng JX. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin. Drug Deliv. 7(1), 49-62 (2010
103. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-Amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 54(2), 169-190 (2002
104. Liu J, Xiao Y, Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J. Pharm. Sci. 93(1), 132-143 (2004
105. Latere Dwan'Isa JP, Rouxhet L, Preat V, Brewster ME, Arien A. Prediction of drug solubility in amphiphilic di-block copolymer micelles: the role of polymer-drug compatibility. Pharmazie. 62(7), 499-504 (2007
106. Forrest ML, Zhao A, Won CY, Malick AW, Kwon GS. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsiloncaprolactone) micelles. J. Control. Release. 116(2), 139-149 (2006
107. Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 23(10), 2417-2426 (2006
108. Danquah M, Fujiwara T, Mahato RI. Self-Assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials. 31(8), 2358-2370 (2010
109. Mundra V, Lu Y, Danquah M, Li W, Miller DD, Mahato RI. Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent. Pharm. Res. 29(11), 3064-3074 (2012
110. Li F, Danquah M, Mahato RI. Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules. 11(10), 2610-2620 (2010
111. Mahmud A, Patel S, Molavi O, Choi P, Samuel J, Lavasanifar A. Self-Associating Poly(ethylene Oxide)-bpoly( Alpha-cholesteryl Carboxylate-epsilon-caprolactone) Block Copolymer for the Solubilization of STAT-3 Inhibitor Cucurbitacin I. Biomacromolecules. 10(3), 471-478 (2009
112. Kataoka K, Matsumoto T, Yokoyama M., et al. Doxorubicinloaded poly(ethylene glycol)-poly(beta-benzyl-L-Aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control. Release. 64(1-3), 143-153 (2000
113. Deng X, Xu X, Lai Y, He B, Gu Z. Novel nanoparticles generated by polymeric amphiphiles with pi-pi conjugated small molecules for anti-Tumor drug delivery. J. Biomed. Nanotechnol. 9(8), 1336-1344 (2013
114. Lai Y, Long Y, Lei Y., et al. A novel micelle of coumarin derivative monoend-functionalized PEG for anti-Tumor drug delivery: in vitro and in vivo study. J. Drug Target. 20(3), 246-254 (2012
115. Shi Y, van Steenbergen MJ, Teunissen EA., et al. Pi-pi stacking increases the stability and loading capacity of thermosensitive polymeric micelles for chemotherapeutic drugs. Biomacromolecules. 14(6), 1826-1837 (2013
116. Lee J, Lee SC, Acharya G, Chang CJ, Park K. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm. Res. 20(7), 1022-1030 (2003
117. Kim JY, Kim S, Papp M, Park K, Pinal R. Hydrotropic solubilization of poorly water-soluble drugs. J. Pharm. Sci. 99(9), 3953-3965 (2010
118. Eckman AM, Tsakalozou E, Kang NY, Ponta A, Bae Y. Drug release patterns and cytotoxicity of PEG-poly(aspartate) block copolymer micelles in cancer cells. Pharm. Res. 29(7), 1755-1767 (2012
119. Kim JO, Kabanov AV, Bronich TK. Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J. Control. Release. 138(3), 197-204 (2009
120. Ye L, Letchford K, Heller M., et al. Synthesis and characterization of carboxylic acid conjugated, hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for cisplatin. Biomacromolecules. 12(1), 145-155 (2011
121. Tian Y, Ravi P, Bromberg L, Hatton TA, Tam KC. Synthesis and aggregation behavior of pluronic F87/poly(acrylic acid) block copolymer in the presence of doxorubicin. Langmuir. 23(5), 2638-2646 (2007
122. Giacomelli C, Schmidt V, Borsali R. Specific interactions improve the loading capacity of block copolymer micelles in aqueous media. Langmuir. 23(13), 6947-6955 (2007
123. Hamaguchi T, Matsumura Y, Suzuki M., et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer. 92(7), 1240-1246 (2005
124. Zhao X, Poon Z, Engler AC, Bonner DK, Hammond PT. Enhanced stability of polymeric micelles based on postfunctionalized poly(ethylene glycol)-b-poly(gammapropargyl L-glutamate): the substituent effect. Biomacromolecules. 13(5), 1315-1322 (2012
125. Kim SH, Tan JP, Nederberg F., et al. Hydrogen bonding-enhanced micelle assemblies for drug delivery. Biomaterials. 31(31), 8063-8071 (2010
126. Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv. Drug Deliv. Rev. 62(2), 272-282 (2010
127. Etrych T, Kovar L, Strohalm J, Chytil P, Rihova B, Ulbrich K. Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-Tumor efficacy. J. Control. Release. 154(3), 241-248 (2011
128. Fox ME, Szoka FC, Frechet JM. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc. Chem. Res. 42(8), 1141-1151 (2009
129. Peterson JJ, Meares CF. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library. Bioconjug. Chem. 9(5), 618-626 (1998
130. Dubowchik GM, Firestone RA, Padilla L., et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13(4), 855-869 (2002
131. Oldham EA, Li C, Ke S, Wallace S, Huang P. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int. J. Oncol. 16(1), 125-132 (2000
132. Liu J, Bauer H, Callahan J, Kopeckova P, Pan H, Kopecek J. Endocytic uptake of a large array of HPMA copolymers: elucidation into the dependence on the physicochemical characteristics. J. Control. Release. 143(1), 71-79 (2010
133. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39(2), 424-431 (1996
134. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83(4), 601-606 (1994
135. Zhang X, Li Y, Chen X., et al. Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate. Biomaterials. 26(14), 2121-2128 (2005
136. Xie Z, Guan H, Chen X., et al. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J. Control. Release. 117(2), 210-216 (2007
137. Riebeseel K, Biedermann E, Loser R., et al. Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-Activity relationships in vitro and in vivo. Bioconjug. Chem. 13(4), 773-785 (2002
138. Veronese FM, Schiavon O, Pasut G., et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug. Chem. 16(4), 775-784 (2005
139. Kopecek J. Polymer-drug conjugates: origins, progress to date and future directions. Adv. Drug Deliv. Rev. 65(1), 49-59 (2013
140. Vasey PA, Kaye SB, Morrison R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5(1), 83-94 (1999
141. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH., et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 12(4), 315-323 (2001
142. Schoemaker NE, van Kesteren C, Rosing H., et al. A Phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br. J. Cancer. 87(6), 608-614 (2002
143. Etrych T, Sirova M, Starovoytova L, Rihova B, Ulbrich K. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol. Pharm. 7(4), 1015-1026 (2010
144. Yang J, Luo K, Pan H, Kopeckova P, Kopecek J. Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates. React. Funct. Polym. 71(3), 294-302 (2011
145. Zhang R, Yang J, Sima M, Zhou Y, Kopecek J. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc. Natl Acad. Sci. USA. 111(33), 12181-12186 (2014
146. Akamatsu K, Yamasaki Y, Nishikawa M, Takakura Y, Hashida M. Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice. J. Pharmacol. Exp. Ther. 290(3), 1242-1249 (1999
147. Sumi H, Kawabe K, Nakajima N. Effect of various polyamino acids and D- And L-Amino acids on the blood fibrinolytic system. Comp. Biochem. Physiol. B. 102(1), 159-162 (1992
148. Li C. Poly(L-glutamic acid)-Anticancer drug conjugates. Adv. Drug Deliv. Rev. 54(5), 695-713 (2002
149. Hurwitz E, Wilchek M, Pitha J. Soluble macromolecules as carriers for daunorubicin. J. Appl. Biochem. 2(1), 25-35 (1980
150. Zunino F, Pratesi G, Micheloni A. Poly(carboxylic acid) polymers as carriers for anthracyclines. J. Control. Release. 10(1), 65-73 (1989
151. Hoes CJT, Grootoonk J, Duncan R., et al. Biological properties of adriamycin bound to biodegradable polymeric carriers. J. Control. Release. 23(1), 37-53 (1993
152. Hoes CJT, Potman W, van Heeswijk WAR., et al. Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin. J. Control. Release. 2(0), 205-213 (1985
153. Li C, Yu DF, Newman RA., et al. Complete regression of well-established tumors using a novel water-soluble poly(Lglutamic acid)-paclitaxel conjugate. Cancer Res. 58(11), 2404-2409 (1998
154. Kim JW, Galanzha EI, Zaharoff DA, Griffin RJ, Zharov VP. Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol. Pharm. 10(3), 813-830 (2013
155. Wang CH, Chiou SH, Chou CP, Chen YC, Huang YJ, Peng CA. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine. 7(1), 69-79 (2011
156. Barth BM, I Altinoglu E, Shanmugavelandy SS., et al. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano. 5(7), 5325-5337 (2011
157. Qiang YG, Yow CM, Huang Z. Combination of photodynamic therapy and immunomodulation: current status and future trends. Med. Res. Rev. 28(4), 632-644 (2008
158. Almeida JP, Drezek RA, Foster AE. Controlling melanoma at local and systemic levels: is a combination of ablative therapy and immunotherapy the way forward? Immunotherapy. 6(2), 109-111 (2014
159. Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br. J. Dermatol. 155(6), 1287-1292 (2006
160. Li X, Naylor MF, Le H., et al. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. Cancer Biol. Ther. 10(11), 1081-1087 (2010
161. Guo L, Yan DD, Yang D., et al. Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano. 8(6), 5670-5681 (2014
162. Bear AS, Kennedy LC, Young JK., et al. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS ONE. 8(7), e69073 (2013
163. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 63(23), 8126-8131 (2003
164. Zhen Z, Tang W, Chuang YJ., et al. Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles. ACS Nano. 8(6), 6004-6013 (2014
165. Selbo PK, Weyergang A, Hogset A., et al. Photochemical internalization provides time- And space-controlled endolysosomal escape of therapeutic molecules. J. Control. Release. 148(1), 2-12 (2010
166. Lou PJ, Lai PS, Shieh MJ, Macrobert AJ, Berg K, Bown SG. Reversal of doxorubicin resistance in breast cancer cells by photochemical internalization. Int. J. Cancer. 119(11), 2692-2698 (2006
167. Selbo PK, Rosenblum MG, Cheung LH, Zhang W, Berg K. Multi-modality therapeutics with potent anti-Tumor effects. photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel. PLoS ONE. 4(8), e6691 (2009
168. Mathews MS, Vo V, Shih EC., et al. Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines. J. Environ. Pathol. Toxicol. Oncol. 31(1), 49-59 (2012
169. Lu HL, Syu WJ, Nishiyama N, Kataoka K, Lai PS. Dendrimer phthalocyanine-encapsulated polymeric micellemediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo. J. Control. Release. 155(3), 458-464 (2011
170. Lai PS, Pai CL, Peng CL, Shieh MJ, Berg K, Lou PJ. Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J. Biomed. Mater. Res. A. 87(1), 147-155 (2008
171. Lai PS, Lou PJ, Peng CL., et al. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J. Control. Release. 122(1), 39-46 (2007
172. Bostad M, Olsen CE, Peng Q, Berg K, Hogset A, Selbo PK. Light-controlled endosomal escape of the novel CD133-Targeting immunotoxin AC133-saporin by photochemical internalization - A minimally invasive cancer stem celltargeting strategy. J. Control. Release. 206, 37-48 (2015
173. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188(6), 759-768 (2010
174. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 26(10), 552-558 (2008
175. Gu FX, Karnik R, Wang AZ., et al. Targeted nanoparticles for cancer therapy. Nano Today. 2(3), 14-21 (2007
176. Weis SM, Cheresh DA. alphaV integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 1(1), a006478 (2011
177. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis. 19(5), 427-436 (2002
178. Hersel U, Dahmen C, Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 24(24), 4385-4415 (2003
179. Phillips E, Penate-Medina O, Zanzonico PB., et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6(260), 260ra149 (2014
180. Wagner S, Rothweiler F, Anhorn MG., et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials. 31(8), 2388-2398 (2010
181. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol. 108(2), 210-214 (1997
182. Ikuta Y, Nakatsura T, Kageshita T., et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin. Cancer Res. 11(22), 8079-8088 (2005
183. Robert G, Gaggioli C, Bailet O., et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 66(15), 7516-7523 (2006
184. Thomas S, Waterman P, Chen S., et al. Development of secreted protein and acidic and rich in cysteine (SPARC) targeted nanoparticles for the prognostic molecular imaging of metastatic prostate cancer. J. Nanomed. Nanotechnol. 2(112), 2157-7439-2-112 (2011
185. Sheng Z, Hu D, Zheng M., et al. Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy. ACS Nano. 8(12), 12310-12322 (2014
186. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albuminbound paclitaxel in head and neck cancer patients. Transl. Oncol. 2(2), 59-64 (2009
187. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 19(9), 899-909 (2008
188. Schneeweiss A, Seitz J, Smetanay K., et al. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res. 34(11), 6609-6615 (2014
189. Shao H, Tang H, Salavaggione OE., et al. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J. Thorac. Oncol. 6(6), 998-1005 (2011
190. Neesse A, Frese KK, Chan DS., et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. 63(6), 974-983 (2014
191. Simberg D, Duza T, Park JH., et al. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl Acad. Sci. USA104(3), 932-936 (2007
192. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121(2), 159-176 (2006
193. Davis ME, Zuckerman JE, Choi CH., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 464(7291), 1067-1070 (2010
194. Pun SH, Tack F, Bellocq NC., et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 3(7), 641-650 (2004
195. Davis ME. The first targeted delivery of siRNA in humans via a self-Assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3), 659-668 (2009
196. Dube DH, Bertozzi CR. Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4(6), 477-488 (2005
197. Matsumoto A, Cabral H, Sato N, Kataoka K, Miyahara Y. Assessment of tumor metastasis by the direct determination of cell-membrane sialic acid expression. Angew. Chem. Int. Ed. Engl. 49(32), 5494-5497 (2010
198. Matsumoto A, Sato N, Kataoka K, Miyahara Y. Noninvasive sialic acid detection at cell membrane by using phenylboronic acid modified self-Assembled monolayer gold electrode. J. Am. Chem. Soc. 131(34), 12022-12023 (2009
199. Deshayes S, Cabral H, Ishii T., et al. Phenylboronic acidinstalled polymeric micelles for targeting sialylated epitopes in solid tumors. J. Am. Chem. Soc. 135(41), 15501-15507 (2013
200. Siegrist W, Solca F, Stutz S., et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 49(22), 6352-6358 (1989
201. Ghanem GE, Libert A, Arnould R, Vercammen A, Lejeune F. Human melanoma targeting with alpha-MSH-melphalan conjugate. Melanoma Res. 1(2), 105-114 (1991
202. Lu W, Xiong C, Zhang G., et al. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin. Cancer Res. 15(3), 876-886 (2009
203. Kim C, Cho EC, Chen J., et al. In vivo molecular photoacoustic tomography of melanomas targeted by bioconjugated gold nanocages. ACS Nano. 4(8), 4559-4564 (2010
204. Falvo E, Tremante E, Fraioli R., et al. Antibody-drug conjugates. targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale. 5(24), 12278-12285 (2013
205. Boussemart L, Routier E, Mateus C., et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib. a study of 42 patients. Ann. Oncol. 24(6), 1691-1697 (2013
206. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 14(1), e11-e18 (2013
207. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer. 6(9), 688-701 (2006
208. Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov. Today. 17(5-6), 253-260 (2012
209. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis. Model. Mech. 1(2-3), 78-82 (2008